Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

To determine whether inclusion of glutamine, selenium, or both in a standard isonitrogenous, isocaloric preparation of parenteral nutrition influenced new infections and mortality among critically ill patients.Randomised, double blinded, factorial, controlled trial.Level 2 and 3 (or combined) critical care units in Scotland. All 22 units were invited, and 10 participated.502 adults in intensive care units and high dependency units for ≥ 48 hours, with gastrointestinal failure and requiring parenteral nutrition.Parenteral glutamine (20.2 g/day) or selenium (500 μg/day), or both, for up to seven days.Primary outcomes were participants with new infections in the first 14 days and mortality. An intention to treat analysis and a prespecified analysis of patients who received ≥ 5 days of the trial intervention are presented. Secondary outcomes included critical care unit and acute hospital lengths of stay, days of antibiotic use, and modified SOFA (Sepsis-related Organ Failure Assessment) score.Selenium supplementation did not significantly affect patients developing a new infection (126/251 v 139/251, odds ratio 0.81 (95% CI 0.57 to 1.15)), except for those who had received ≥ 5 days of supplementation (odds ratio 0.53 (0.30 to 0.93)). There was no overall effect of glutamine on new infections (134/250 v 131/252, odds ratio 1.07 (0.75 to 1.53)), even if patients received ≥ 5 days of supplementation (odds ratio 0.99 (0.56 to 1.75)). Six month mortality was not significantly different for selenium (107/251 v 114/251, odds ratio 0.89 (0.62 to 1.29)) or glutamine (115/250 v 106/252, 1.18 (0.82 to 1.70)). Length of stay, days of antibiotic use, and modified SOFA score were not significantly affected by selenium or glutamine supplementation.The primary (intention to treat) analysis showed no effect on new infections or on mortality when parenteral nutrition was supplemented with glutamine or selenium. Patients who received parenteral nutrition supplemented with selenium for ≥ 5 days did show a reduction in new infections. This finding requires confirmation. Trial registration Current Controlled Trials ISRCTN87144826.

Original publication

DOI

10.1136/bmj.d1542

Type

Journal article

Journal

BMJ (Clinical research ed.)

Publication Date

17/03/2011

Volume

342

Addresses

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH4 2XU, UK. p.andrews@ed.ac.uk

Keywords

Scottish Intensive care Glutamine or seleNium Evaluative Trial Trials Group, Humans, Cross Infection, Critical Illness, Selenium, Glutamine, Drug Combinations, Treatment Outcome, Parenteral Nutrition, Critical Care, Double-Blind Method, Quality of Life, Dietary Supplements, Aged, Middle Aged, Female, Male